America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy‘.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
What are the potential side effects of the new cancer cell-killing drug AOH1996 compared to traditional chemotherapy?
**Interview with Dr. Linda Malkas on Innovative Cancer Treatment**
**Editor:** Today, we have the pleasure of speaking with Dr. Linda Malkas, a leading figure in cancer research at the City of Hope Hospital. Dr. Malkas, can you start by telling us about your recent work on the new cancer cell-killing drug, AOH1996?
**Dr. Malkas:** Thank you for having me. AOH1996 is a targeted chemotherapy drug that we’ve developed over the past two decades. It effectively destroys solid tumors by specifically targeting a protein variant known as PCNA, which is critical for DNA replication and tumor growth in cancer cells.
**Editor:** That sounds promising. How does AOH1996 differentiate between cancer cells and healthy cells?
**Dr. Malkas:** The mechanism is quite ingenious. We liken PCNA to an airline terminal hub; it’s essential for the normal functioning of cells. However, in cancer cells, PCNA is mutated. AOH1996 disrupts the normal reproductive cycle of these cancer cells while leaving healthy cells largely unaffected. This “blizzard” effect we described really illustrates how we can selectively halt the proliferation of cancer cells.
**Editor:** The findings are impressive, especially considering they were tested on over 70 different cancer cell lines. What are the next steps in your research?
**Dr. Malkas:** We’re excited to move forward with clinical trials in humans. Our results in the lab indicate strong potential for AOH1996 against various cancer types, including breast, prostate, and lung cancers. We hope to see similar efficacy in clinical settings.
**Editor:** What do you think this development means for the future of cancer treatment?
**Dr. Malkas:** This represents a significant advancement in personalized medicine. A targeted approach like AOH1996 could mean fewer side effects and more effective treatment options for patients. Ultimately, we aim to improve survival rates and enhance the quality of life for those battling cancer.
**Editor:** Thank you, Dr. Malkas, for sharing this groundbreaking research with us. We look forward to following your progress!
**Dr. Malkas:** Thank you for your interest. It’s an exciting time for cancer research, and I appreciate the opportunity to discuss our work!
